Risk of subsequent malignant neoplasms in long-term Hereditary retinoblastoma survivors after chemotherapy and radiotherapy

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages 3284-3290

  Wong, Jeannette R ^a   Morton, Lindsay M ^a   Tucker, Margaret A ^a   Abramson, David H ^b   Seddon, Johanna M ^c   Sampson, Joshua N ^a   Kleinerman, Ruth A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; TRETAMINE;

ARTICLE; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CHILD; EPITHELIUM TUMOR; FEMALE; FOLLOW UP; HUMAN; INFANT; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PRESCHOOL CHILD; RETINOBLASTOMA; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; LONGITUDINAL STUDY; MULTICENTER STUDY; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; RETINAL NEOPLASMS; RETROSPECTIVE STUDY; RISK; SURVIVAL RATE; SURVIVOR; UNITED STATES;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; NEOPLASMS, SECOND PRIMARY; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; SURVIVORS; TRIETHYLENEMELAMINE; UNITED STATES;

EID: 84907546653     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.7844     Document Type: Article

References (59)

1. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820-823, 1971
2. Pendergrass TW, Davis S: Incidence of retinoblastoma in the United States. Arch Ophthalmol 98:1204-1210, 1980
3. Broaddus E, Topham A, Singh AD: Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93:24-27, 2009
4. Kleinerman RA, Yu CL, Little MP, et al: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 30:950-957, 2012
5. Kleinerman RA, Tucker MA, Tarone RE, et al: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 23:2272-2279, 2005
6. Eng C, Li FP, Abramson DH, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128, 1993
7. Wong FL, Boice JD Jr, Abramson DH, et al: Cancer incidence after retinoblastoma: Radiation dose and sarcoma risk. JAMA 278:1262-1267, 1997
8. Derkinderen DJ, Koten JW, Wolterbeek R, et al: Non-ocular cancer in hereditary retinoblastoma survivors and relatives. Ophthalmic Paediatr Genet 8:23-25, 1987
9. Kleinerman RA, Schonfeld SJ, Tucker MA: Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res 2:15, 2012
10. Kleinerman RA, Tucker MA, Abramson DH, et al: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99:24-31, 2007
11. Abramson DH, Frank CM: Second nonocular tumors in survivors of bilateral retinoblastoma: A possible age effect on radiation-related risk. Ophthalmology 105:573-579, 1998; discussion 579-580
12. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al: Second primary tumors in hereditary retinoblastoma: A register-based study, 1945-1997-Is there an age effect on radiation-related risk? Ophthalmology 108:1109-1114, 2001
13. Fletcher O, Easton D, Anderson K, et al: Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96:357-363, 2004
14. Marees T, Moll AC, Imhof SM, et al: Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up. J Natl Cancer Inst 100:1771-1779, 2008
15. Ellsworth RM: The practical management of retinoblastoma. Trans Am Ophthalmol Soc 67:462-534, 1969
16. Reese AB, Hyman GA, Merriam GR Jr, et al: The treatment of retinoblastoma by radiation and triethylene melamine. Am J Ophthalmol 43:865-872, 1957
17. Reese AB, Hyman GA, Merriam GR Jr, et al: Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol 53:505-513, 1954
18. Pillay R, Graham-Pole J, Novak L, et al: Successful treatment of osteogenic sarcoma developing as a second cancer in childhood. Am J Pediatr Hematol Oncol 5:103-105, 1983
19. Draper GJ, Sanders BM, Kingston JE: Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661-671, 1986
20. Hawkins MM, Wilson LM, Burton HS, et al: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88:270-278, 1996
21. Schlienger P, Campana F, Vilcoq JR, et al: Nonocular second primary tumors after retinoblastoma: Retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. Am J Clin Oncol 27:411-419, 2004
22. Newton WA Jr, Meadows AT, Shimada H, et al: Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 67:193-201, 1991
23. Rodriguez-Galindo C, Wilson MW, Haik BG, et al: Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21:2019-2025, 2003
24. Chantada GL, Fandiño AC, Casak SJ, et al: Activity of topotecan in retinoblastoma. Ophthalmic Genet 25:37-43, 2004
25. Mallipatna AC, Dimaras H, Chan HS, et al: Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 129:738-745, 2011
26. Schefler AC, Abramson DH: Retinoblastoma: What is new in 2007-2008. Curr Opin Ophthalmol 19:526-534, 2008
27. Schouten-Van Meeteren AY, Moll AC, Imhof SM, et al: Overview: Chemotherapy for retinoblastoma-An expanding area of clinical research. Med Pediatr Oncol 38:428-438, 2002
28. Jenkinson HC, Winter DL, Marsden HB, et al: A study of soft tissue sarcomas after childhood cancer in Britain. Br J Cancer 97:695-699, 2007
29. Le Vu B, de Vathaire F, Shamsaldin A, et al: Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 77:370-377, 1998
30. Tucker MA, D'Angio GJ, Boice JD Jr, et al: Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317:588-593, 1987
31. Yu CL, Tucker MA, Abramson DH, et al: Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 101:581-591, 2009
32. Steliarova-Foucher E, Stiller C, Lacour B, et al: International Classification of Childhood Cancer, third edition. Cancer 103:1457-1467, 2005
33. Breslow NE, Lubin JH, Marek P, et al: Multiplicative models and cohort analysis. J Am Stat Assoc 78:1-12, 1983
34. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141-1154, 1988
35. Aerts I, Pacquement H, Doz F, et al: Outcome of second malignancies after retinoblastoma: A retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 40:1522-1529, 2004
36. Turaka K, Shields CL, Meadows AT, et al: Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 59:121-125, 2012
37. Gombos DS, Hungerford J, Abramson DH, et al: Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor? Ophthalmology 114:1378-1383, 2007
38. MacCarthy A, Bayne AM, Brownbill PA, et al: Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 108:2455-2463, 2013
39. Amant F, de la Rey M, Dorfling CM, et al: PTEN mutations in uterine sarcomas. Gynecol Oncol 85:165-169, 2002
40. de Vos S, Wilczynski SP, Fleischhacker M, et al: p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol 54:205-208, 1994
41. Dei Tos AP, Maestro R, Doglioni C, et al: Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 148:1037-1045, 1996
42. Polsky D, Mastorides S, Kim D, et al: Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. Histol Histopathol 21:743-752, 2006
43. Zhai YL, Nikaido T, Orii A, et al: Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 75:453-459, 1999
44. Otaño-Joos M, Mechtersheimer G, Ohl S, et al: Analysis of chromosome copy number changes in leiomyosarcoma through molecular cytogenetic methods [in German]. Verh Dtsch Ges Pathol 82:207-209, 1998
45. Gerstenblith MR, Goldstein AM, Tucker MA: Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am 24:885-906, 2010
46. Leone G, Fianchi L, Pagano L, et al: Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 184:39-45, 2010
47. Morton LM, Curtis RE, Linet MS, et al: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Differences by lymphoma subtype. J Clin Oncol 28:4935-4944, 2010
48. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94:182-192, 2002
49. Morton LM, Dores GM, Curtis RE, et al: Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 31:3369-3377, 2013
50. Nottage K, McFarlane J, Krasin MJ, et al: Secondary colorectal carcinoma after childhood cancer. J Clin Oncol 30:2552-2558, 2012
51. Henderson TO, Rajaraman P, Stovall M, et al: Risk factors associated with secondary sarcomas in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 84:224-230, 2012
52. Chantada GL, Fandino AC, Carcaboso AM, et al: A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 50:1492-1496, 2009
53. Green DM, Nolan VG, Goodman PJ, et al: The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 61:53-67, 2014
54. Draper GJ, Sanders BM, Brownbill PA, et al: Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. Br J Cancer 66:211-219, 1992
55. MacCarthy A, Birch JM, Draper GJ, et al: Retinoblastoma in Great Britain 1963-2002. Br J Ophthalmol 93:33-37, 2009
56. Vogel F: Genetics of retinoblastoma. Hum Genet 52:1-54, 1979
57. Houdayer C, Gauthier-Villars M, Laugé A, et al: Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat 23:193-202, 2004
58. Marees T, van Leeuwen FE, Schaapveld M, et al: Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer 46:2052-2058, 2010
59. Foster MC, Kleinerman RA, Abramson DH, et al: Tobacco use in adult long-term survivors of retinoblastoma. Cancer Epidemiol Biomarkers Prev 15:1464-1468, 2006